Tsiligianni Ioanna, Kampouraki Maria, Ierodiakonou Despo, Poulonirakis Ioannis, Papadokostakis Polyvios
Department of Social Medicine, Faculty of Medicine, University of Crete, Herkalion, Crete, Greece,
Primary Care Practice, Health Center of Moires, Heraklion, Crete, Greece.
Int J Chron Obstruct Pulmon Dis. 2019 Mar 1;14:547-556. doi: 10.2147/COPD.S185362. eCollection 2019.
GOLD guidelines classify COPD patients into A-D groups based on health status as assessed by COPD Assessment Test (CAT) or mMRC tools and exacerbations and recommend single or dual long-acting bronchodilators as maintenance therapy, with additional inhaled corticosteroids (ICS) if the disease remains uncontrolled. We aimed to classify primary care COPD patients into A-D groups, assess usual treatment and adherence to guidelines, potential mismatches between CAT-and mMRC-based classification and described symptoms within groups.
A total of 257 primary care COPD patients were enrolled between 2015 and 2016 in Greece. Physicians used structured interviews to collect cross-sectional data including demographics, symptoms, CAT, mMRC scores, and medications. Patients were classified into A-D groups based on CAT and mMRC, and prevalence of symptoms and medication was estimated within A-D groups. Interviews with physicians were also performed to explore additional issues about treatment and adherence to guidelines.
Mean (SD) age was 65 (12.3) years with 79% males. The majority of patients reported uncontrolled symptoms (91% and 61% with ≥10 CAT or ≥2 mMRC scores, respectively). Thirty-seven percentage had $2 exacerbations in the past year. Group B was the largest followed by Groups D, A, and C. Patients were classified as more severe by CAT than by mMRC. In all groups, the majority were treated with combined long-acting beta agonist/ICS (> 50%). When patients were asked to report their main symptoms, dyspnea and cough were the most important symptoms mentioned, and there was a great variation between the A-D groups. However, Groups A-C reported mainly morning symptoms, whereas Group D suffered symptoms all day. Physicians reported a significant number of barriers to implementing guidelines, eg, frequent lack of guideline updates, access to diagnostic procedures, and prescription-reimbursement issues.
Our study confirms poor adherence to guidelines regarding treatment with an overuse of ICS and important barriers to implementation. A mismatch in classification occurs depending on the tool used, which can mislead clinicians in their choice of treatment.
慢性阻塞性肺疾病(COPD)全球倡议(GOLD)指南根据慢性阻塞性肺疾病评估测试(CAT)或改良英国医学研究委员会(mMRC)工具评估的健康状况以及急性加重情况,将COPD患者分为A - D组,并推荐使用单一或双重长效支气管扩张剂作为维持治疗,如果疾病仍未得到控制,则加用吸入性糖皮质激素(ICS)。我们旨在将基层医疗中的COPD患者分为A - D组,评估常规治疗及对指南的依从性,以及基于CAT和mMRC的分类与组内所述症状之间可能存在的不匹配情况。
2015年至2016年期间,希腊共纳入了257例基层医疗COPD患者。医生通过结构化访谈收集横断面数据,包括人口统计学信息、症状、CAT、mMRC评分及用药情况。根据CAT和mMRC将患者分为A - D组,并估计A - D组内症状和药物的患病率。还对医生进行了访谈,以探讨有关治疗和指南依从性的其他问题。
平均(标准差)年龄为65(12.3)岁,男性占79%。大多数患者报告症状未得到控制(分别有91%和61%的患者CAT评分≥10或mMRC评分≥2)。37%的患者在过去一年中有≥2次急性加重。B组人数最多,其次是D组、A组和C组。与mMRC相比,CAT将患者分类为更严重。在所有组中,大多数患者接受长效β受体激动剂/ICS联合治疗(>50%)。当要求患者报告其主要症状时,呼吸困难和咳嗽是提及最多的重要症状,且A - D组之间存在很大差异。然而,A - C组主要报告早晨症状,而D组全天都有症状。医生报告在实施指南方面存在大量障碍,例如,经常缺乏指南更新、难以获得诊断程序以及处方报销问题。
我们的研究证实,在治疗方面对指南的依从性较差,存在ICS过度使用的情况,并且在实施方面存在重要障碍。根据所使用的工具,分类会出现不匹配,这可能会误导临床医生选择治疗方法。